Year 7, Number 27, January 2005

 

Oncology

 

 


*Moriguchi SM.; **De Luca LA.; *Griva BL.; *Tinois E.; **Uemura G.; *Koga K.; **Vespoli H.

*Nuclear Medicine Technical Sector and **Laurival A de Luca Mastology Evaluation Center, Hospital das Clinicas - Medicine School, Paulista State University, Botucatu - Unesp

Correspondencia:

Sonia M. Moriguchi
E-mail: soniamoriguchi@terra.com.br
Fono:1796017995 / 14381161

Cita/Reference:
Moriguchi SM.; De Luca LA.; Griva BL.et al. Scintimammography with 99mTc sestamibi of suspect nodules - Quantitative analysis. Alasbimn Journal 7(27): January 2005



Scintimammography with 99mTc sestamibi of suspect nodules - Quantitative analysis


INTRODUCTION: The lack of standardization to interpret scintimammograms directly influences the efficiency of the method. Small lesions can present localized low-intensity 99mTc sestamibi uptake, which can be classified as positive by some professionals and negative by others. Quantitative and semi-quantitative analyses of suspect lesions have been suggested as a technique of improving the accuracy of detecting breast tumors. Unfortunately, until now, there is no consensus about the best method to calculate an index of malignancy indicative values.

AIM: To measure the intensity of 99mTc sestamibi uptake in breast nodules.

PATIENTS AND METHOD: Indexes of uptake, calculated as counts/pixels observed in regions of interest identified on scintimammograms of suspect lesions and in the contralateral breast, were compared for 98 nodules with localized uptake of 99mTc sestamibi.

RESULTS: The mean of the indexes was significantly greater in malignant nodules (n = 93; I = 2.9 ± 1.73; p < 0.001), including ductal carcinomas (n = 83; I = 3.0 ± 1.79; p < 0.001) and lobular carcinomas (n = 03; I = 2.6 ± 0.65; p < 0.05) compared to benign nodules (n = 05; I = 1.6 ± 0.41). Mucinous carcinomas (n = 02; I = 2.1 ± 1.12), medullary carcinomas (n = 02; I = 1.7 ± 0.57) and papillary carcinomas (n = 01; I = 1.5) as well as high-risk intraductal lesions (carcinoma in situ) (n = 02; I = 1.7 ± 0.4) demonstrated lower indexes similar to indexes observed in benign nodules. The range of the index variations was greater for ductal carcinomas (1.0 - 11.0), compared to other lesions such as lobular (2.1 - 3.3), mucinous (1.3 - 2.9), medullary (1.3 - 2.1) high-risk intraductal lesion (1.4 - 2.0) and benign nodules (1.2 - 2.1).

CONCLUSIONS: Higher indexes are observed in malignant nodules, especially among ductal and lobular carcinomas. Indexes of less than 2.11 are unspecific and do not discriminate the nature of the nodule. As the index increases, the probability that the tumor is malignant also increases, with ductal carcinomas having the highest indexes.

 


Correlation Between PSA Level, Gleason Score and Bone Scan in Staging of Prostate Cancer Patients | Lymphatic Mapping and Sentinel Node Detection using 99mTc-Phytate in Cervix Cancer - 55 cases | Use of 99mTc-Phytate for Lymphoscintigraphy and Sentinel Node Biopsy in 858 Patients with Breast Cancer | Whole-Body Tc-99m Sestamibi Scintigraphy in the Pre-Operative Evaluation of differentiated Thyroid Carcinoma | Lymphatic Mapping and Detection of Sentinel Lymph Node in Vulvar Cancer | Calculation of a 99mTc sestamibi concentration index in suspect breast lesions. Where should the area of interest necessary to establish a reference value be? | Scintimammography with 99mTc sestamibi of suspect nodules - Quantitative analysis | Efficiency of scintimammography with 99mTc sestamibi in the detection of cancer | Identification of Sentinel Node in Breast Cancer: Injection of the radiopharmaceutical in four points | The influence of histological grading in the detection of breast carcinoma on scintimammography | Determinant factors of thyroid function outcome in patients with graves' Disease after radioiodine therapy | Parathyroid Scintigraphy with 99mTc-Sestamibi: The Value of Sequential Images to Plan Minimally Invasive Radioguided Parathyroidectomy | 99mTc -Sestamibi in differential diagnosis of congenital hypothyroidism in children under hormone therapy | Print

 

 

Sitio desarrollado por SISIB - Universidad de Chile